AbbVie Inc (NYSE:ABBV) has sought a joint venture with its target discovery portfolio company, Emergent Technologies Inc, Pure MHC. The collaboration between the two will seek to identify a library of peptide targets that will necessitate further research across multiple tumor types.
AbbVie’s pipeline spans significant areas of medical need the likes of oncology, immunology, neuroscience and virology. This is why Chief Executive Officer at ETI and Pure MHC Thomas Harlan acknowledges, “We are excited to partner with AbbVie in the immuno-oncology space leveraging Pure MHC’s over 15 years of peptide target discovery with AbbVie’s deep clinical expertise to utilize these targets in new and improved therapies for the treatment of cancer.”
Combined efforts hope to accelerate the pace of innovation: Innovation has fully become the key driver of the world even in the simplest of tasks. Hence combined efforts are important according to AbbVie’s research and development and chief scientific officer Michael Severino. He emphasizes that the development of tomorrow’s therapies is dependent on today’s investment in leading technologies and scientific achievements. It will also facilitate an enhanced pace of innovation into new medicines for the next-generation of medical treatment.
Read more: https://marketexclusive.com/emergent-technologies-pure-mhc-explores-new-collaboration-abbvie-inc-nyseabbv/68396/